HOME >> BIOLOGY >> NEWS
Incubator company at NJIT develops lifesaving MRI coil for small animals

NEWARK, Mar 7-Supertron, a start-up technology company housed in the small business incubators at New Jersey Institute of Technology (NJIT, announced today that it has begun developing a cryogenic coil to improve Magnetic Resonance Imaging (MRI) scanners.

"The new coil will be well suited for animal imaging," said Supertron President Jon T. DeVries. "Small animal models, particularly genetically engineered mice, are becoming an increasingly powerful tool for cancer researchers. This potential has not been fully realized to date due to the need to sacrifice the animal and conduct tissue and molecular analysis thereby losing out on the opportunity to observe, in vivo, the evolution of the processes under study."

The New Jersey Economic Development Authority (NJEDA) recently awarded the company a $250,000 Springboard II grant. This money follows an earlier $2 million grant in 2003 from the National Institute of Science and Technology (NIST) at the US Department of Commerce.

Erzhen Gao, PhD, director of research and development for the company will lead the effort. The tests will be conducted through a series of animal studies conducted at University of Medicine and Dentistry of New Jersey (UMDNJ).

"Eventually, we hope to see our system upgrade existing MRI scanners because our coils can enhance installed MRIs, enabling them to produce cleaner, clearer and easier-to-read images at an affordable price," said DeVries. A medical school is testing another Supertron coil system developed for low field MRIs of the human head.

DeVries said interest in small animal imaging is growing and cited programs doing this research including the Small Animal Imaging Resource Program at the National Cancer Institute.

Coils are the receiving antenna of the radio waves emitted during an MRI scan and are essential to the MRI's operation. An MRI clinic may have as many as ten coils, each designed for specific anatomical parts (spine, he
'"/>

Contact: Sheryl Weinstein
sheryl.m.weinstein@njit.edu
973-596-3436
New Jersey Institute of Technology
7-Mar-2005


Page: 1 2 3

Related biology news :

1. Colorado company to sell medical food products based on Wake Forest discovery
2. Spin-out company seeks medicines from South American rain forests
3. New company will seek drugs against diabetes and cancer
4. EMBL scientists found start-up company to develop anti-cancer drugs
5. New waste water technology company wins 2006 EUREKA Lynx Award
6. Yale technology spins out varicose vein device company: Vascular Insights, LLC
7. Innovative technology for production of new pharmaceuticals forms basis of new company
8. Ossur acquires US orthotics company Royce Medical
9. USF spin-out company Saneron CCEL wins federal award for cell therapy
10. Idaho lab, Utah company achieve major milestone in hydrogen research
11. N.C. A&T food scientist develops process for allergen-free peanuts

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: